Skip to content

Dyne Therapeutics

US · DYN #2540 by market cap Listed 2020
15.50 -0.53 -3.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • RBC Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/6
  • Company notice
    Walter Dyn: Measures for the Management of Market Capitalization of Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/8/21
  • Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/11/6
  • Rating change
    Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/9/30
  • LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/9/30
  • Company notice
    Walter Dyn: Internal Review System for Information Disclosure and Responses on the Interactive Platform of Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/10/30
  • Rating change
    J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Sell Rating, Announces Target Price $10
    Market Newswire · 2026/9/11
  • Rating change
    Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $37
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $26 to $50
    Market Newswire · 2026/9/9
  • Rating change
    Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26
    Market Newswire · 2026/9/10
  • H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $32
    Market Newswire · 2026/11/6
  • Rating change
    Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47
    Market Newswire · 2026/9/29
  • Rating change
    Jefferies Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/9/8
  • Company notice
    Walter Dyn: Compensation Management System for Directors and Senior Management of Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/4/24
  • Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $41
    Market Newswire · 2026/11/12
  • Rating change
    Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/8/25
  • Company notice
    Walter Dyn: Summary Table of Non-Operating Fund Occupancy and Other Related Party Transactions for the First Half of 2026, Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/8/21
  • Rating change
    Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36
    Market Newswire · 2026/9/10
  • Company notice
    Walter Dyn: 2025 Annual Internal Control Audit Report of Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/4/24
  • Rating change
    H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/8/17
  • Rating change
    Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/8/5
  • Rating change
    Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45
    Market Newswire · 2026/7/31
  • Rating change
    A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47
    Market Newswire · 2026/7/31
  • H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $32
    Market Newswire · 2026/9/30
  • Company notice
    Walter Dyn: Special Statement on Non-Operating Fund Occupancy and Other Related Party Transactions for the Year 2025 of Shandong Walter Dyn Health Co., Ltd.
    SZSI · 2026/4/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Dyne Therapeutics discussion 0 comments

Add a comment